ITGA4&ITGB7 Recombinant Monoclonal Antibody

The α4β7 integrin heterodimer plays a central role in lymphocyte trafficking to gut-associated lymphoid tissues, mediating adhesion to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on high endothelial venules. This interaction is fundamental to mucosal immunity and has emerged as a critical therapeutic target in inflammatory bowel diseases, where disrupting α4β7-mediated homing can reduce pathogenic lymphocyte infiltration into intestinal tissues. Understanding the expression patterns and functional dynamics of this integrin complex is essential for researchers investigating mucosal immunology, autoimmune conditions, and novel therapeutic strategies.

This recombinant monoclonal antibody, clone 20C1, targets the ITGA4 and ITGB7 subunits that comprise the α4β7 heterodimer. Developed using recombinant technology, this antibody offers the consistency and reproducibility that demanding experimental workflows require. Each lot is derived from a defined sequence, eliminating the batch-to-batch variability that can compromise longitudinal studies or multi-site collaborations. The human IgG2 isotype format and affinity-chromatography purification ensure high specificity and minimal background in your applications.

Validation studies demonstrate reliable performance in immunohistochemistry on human tissues. Testing in paraffin-embedded human lymph node and tonsil sections at 1:50 dilution using citrate buffer antigen retrieval reveals clear staining patterns consistent with expected lymphocyte distribution in these secondary lymphoid organs. The antibody is also validated for ELISA applications, with recommended IHC dilutions ranging from 1:50 to 1:200 to accommodate different tissue types and detection systems.

This antibody serves researchers investigating lymphocyte homing mechanisms, mucosal immunity, inflammatory bowel disease pathogenesis, and the development of integrin-targeted therapeutics for autoimmune conditions affecting the gastrointestinal tract.